Reports from the fifth edition of CAGI: The Critical Assessment of Genome Interpretation.

CAGI Critical Assessment of Genome Interpretation SNP cancer genetics genetic variation genomics variant impact predictors

Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
09 2019
Historique:
received: 16 07 2019
accepted: 19 07 2019
pubmed: 25 7 2019
medline: 14 3 2020
entrez: 24 7 2019
Statut: ppublish

Résumé

Interpretation of genomic variation plays an essential role in the analysis of cancer and monogenic disease, and increasingly also in complex trait disease, with applications ranging from basic research to clinical decisions. Many computational impact prediction methods have been developed, yet the field lacks a clear consensus on their appropriate use and interpretation. The Critical Assessment of Genome Interpretation (CAGI, /'kā-jē/) is a community experiment to objectively assess computational methods for predicting the phenotypic impacts of genomic variation. CAGI participants are provided genetic variants and make blind predictions of resulting phenotype. Independent assessors evaluate the predictions by comparing with experimental and clinical data. CAGI has completed five editions with the goals of establishing the state of art in genome interpretation and of encouraging new methodological developments. This special issue (https://onlinelibrary.wiley.com/toc/10981004/2019/40/9) comprises reports from CAGI, focusing on the fifth edition that culminated in a conference that took place 5 to 7 July 2018. CAGI5 was comprised of 14 challenges and engaged hundreds of participants from a dozen countries. This edition had a notable increase in splicing and expression regulatory variant challenges, while also continuing challenges on clinical genomics, as well as complex disease datasets and missense variants in diseases ranging from cancer to Pompe disease to schizophrenia. Full information about CAGI is at https://genomeinterpretation.org.

Identifiants

pubmed: 31334884
doi: 10.1002/humu.23876
pmc: PMC7329230
mid: NIHMS1568236
doi:

Types de publication

Congress Introductory Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1197-1201

Subventions

Organisme : NHGRI NIH HHS
ID : R13 HG006650
Pays : United States
Organisme : NHGRI NIH HHS
ID : U41 HG007346
Pays : United States
Organisme : National Human Genome Research Institute and National Cancer Institute
ID : U41 HG007346 and R13 HG006650
Pays : International

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Hum Mutat. 2019 Sep;40(9):1463-1473
pubmed: 31283071
Hum Mutat. 2019 Sep;40(9):1414-1423
pubmed: 31243847
Hum Mutat. 2019 Sep;40(9):1280-1291
pubmed: 31106481
Hum Mutat. 2019 Sep;40(9):1215-1224
pubmed: 31301154
Hum Mutat. 2019 Sep;40(9):1579-1592
pubmed: 31144781
Hum Mutat. 2019 Sep;40(9):1455-1462
pubmed: 31066146
Hum Mutat. 2020 Feb;41(2):347-362
pubmed: 31680375
Hum Mutat. 2017 Sep;38(9):1039-1041
pubmed: 28817245
Hum Mutat. 2019 Sep;40(9):1261-1269
pubmed: 31090248
Hum Mutat. 2019 Sep;40(9):1346-1363
pubmed: 31209962
Hum Mutat. 2019 Sep;40(9):1321-1329
pubmed: 31144782
Hum Mutat. 2019 Sep;40(9):1424-1435
pubmed: 31106920
Hum Mutat. 2019 Sep;40(9):1364-1372
pubmed: 31066479
Hum Mutat. 2019 Sep;40(9):1330-1345
pubmed: 31144778
Hum Mutat. 2019 Sep;40(9):1252-1260
pubmed: 31066132
Hum Mutat. 2019 Sep;40(9):1392-1399
pubmed: 31209948
Hum Mutat. 2019 Sep;40(9):1373-1391
pubmed: 31322791
Hum Mutat. 2019 Sep;40(9):1593-1611
pubmed: 31112341
Hum Mutat. 2019 Sep;40(9):1225-1234
pubmed: 31297895
Hum Mutat. 2019 Sep;40(9):1495-1506
pubmed: 31184403
Hum Mutat. 2017 Sep;38(9):1240-1250
pubmed: 28220625
Hum Mutat. 2019 Sep;40(9):1519-1529
pubmed: 31342580
Hum Mutat. 2019 Sep;40(9):1314-1320
pubmed: 31140652
Hum Mutat. 2019 Sep;40(9):1474-1485
pubmed: 31260570
Hum Mutat. 2019 Sep;40(9):1400-1413
pubmed: 31074541
Hum Mutat. 2019 Sep;40(9):1486-1494
pubmed: 31268618
Hum Mutat. 2019 Sep;40(9):1292-1298
pubmed: 31228310
Hum Mutat. 2019 Sep;40(9):1436-1454
pubmed: 31317604
Hum Mutat. 2019 Sep;40(9):1202-1214
pubmed: 31283070
Hum Mutat. 2019 Sep;40(9):1612-1622
pubmed: 31241222
Hum Mutat. 2019 Sep;40(9):1546-1556
pubmed: 31294896
Hum Mutat. 2019 Sep;40(9):1530-1545
pubmed: 31301157
Hum Mutat. 2019 Sep;40(9):1243-1251
pubmed: 31070280
Hum Mutat. 2019 Sep;40(9):1507-1518
pubmed: 31228295
Hum Mutat. 2019 Sep;40(9):1270-1279
pubmed: 31074545
Hum Mutat. 2019 Sep;40(9):1235-1242
pubmed: 31070294
Hum Mutat. 2019 Sep;40(9):1299-1313
pubmed: 31131957
Hum Mutat. 2019 Sep;40(9):1557-1578
pubmed: 31131967

Auteurs

Gaia Andreoletti (G)

Department of Plant and Microbial Biology, University of California, Berkeley, California.

Lipika R Pal (LR)

Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland.

John Moult (J)

Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland.
Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland.

Steven E Brenner (SE)

Department of Plant and Microbial Biology, University of California, Berkeley, California.
Center for Computational Biology, University of California, Berkeley, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH